Advair, Serevent add "black box"
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's asthma treatments Advair Diskus (fluticasone/salmeterol) and Serevent (salmeterol) labeling is revised to include "black box" warnings on an increased risk of asthma-related deaths in salmeterol-treated patients. Warnings for both products state that patients receiving salmeterol on top of a usual asthma regimen "showed a small but significant increase in asthma-related deaths" vs. placebo, an Aug. 14 FDA "Talk Paper" states. The effect was more pronounced in African American patients. The finding comes from GSK's Salmeterol Multicenter Asthma Research Trial (SMART); the firm alerted physicians in January that it had halted the study due to the findings and enrollment difficulties. "It is not known whether the findings seen with Serevent…would apply to Advair," Advair's labeling states. FDA is considering the possibility of a beta agonist class effect...
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.